BACKGROUND: CD44, a transmembrane glycoprotein receptor, plays a major role in tumor progression and metastasis. OBJECTIVE: To evaluate the expression of CD44 standard (CD44s) and its variant 6 (CD44v6) in normal and neoplastic lung tissue and correlate it with prognostic factors in lung cancer. METHODS: The study included 52 non-small cell lung carcinomas (NSCLC) (21 squamous cell carcinomas and 31 adenocarcinomas), 15 small cell lung carcinomas (SCLC) and 8 carcinoid tumors. Expression of CD44s and CD44v6 was evaluated by immunohistochemistry and correlated with lung cancer prognostic factors. RESULTS: All squamous cell carcinomas expressed both CD44s and CD44v6. Adenocarcinomas expressed CD44s in 39% of cases and CD44v6 in 45%. Carcinoid tumors expressed only CD44s in 88% of cases. All SCLCs were negative for both CD44s and CD44v6. A restricted panel consisting of CD44s and CD44v6 will discriminate NSCLC from SCLC with a sensitivity of 67% and a specificity of 100%. In adenocarcinoma CD44s expression was significantly correlated with lymph node metastases (p=0.007) while CD44v6 expression was more significantly associated with tumor size (p=0.0032). CONCLUSIONS: CD44s and CD44v6 are expressed in certain types of lung cancer. In adenocarcinoma CD44s and CD44v6 expression is significantly correlated with lymph node metastases and tumor size.
BACKGROUND:CD44, a transmembrane glycoprotein receptor, plays a major role in tumor progression and metastasis. OBJECTIVE: To evaluate the expression of CD44 standard (CD44s) and its variant 6 (CD44v6) in normal and neoplastic lung tissue and correlate it with prognostic factors in lung cancer. METHODS: The study included 52 non-small cell lung carcinomas (NSCLC) (21 squamous cell carcinomas and 31 adenocarcinomas), 15 small cell lung carcinomas (SCLC) and 8 carcinoid tumors. Expression of CD44s and CD44v6 was evaluated by immunohistochemistry and correlated with lung cancer prognostic factors. RESULTS: All squamous cell carcinomas expressed both CD44s and CD44v6. Adenocarcinomas expressed CD44s in 39% of cases and CD44v6 in 45%. Carcinoid tumors expressed only CD44s in 88% of cases. All SCLCs were negative for both CD44s and CD44v6. A restricted panel consisting of CD44s and CD44v6 will discriminate NSCLC from SCLC with a sensitivity of 67% and a specificity of 100%. In adenocarcinoma CD44s expression was significantly correlated with lymph node metastases (p=0.007) while CD44v6 expression was more significantly associated with tumor size (p=0.0032). CONCLUSIONS: CD44s and CD44v6 are expressed in certain types of lung cancer. In adenocarcinoma CD44s and CD44v6 expression is significantly correlated with lymph node metastases and tumor size.
Authors: Álvaro Ruibal; Pablo Aguiar; María Carmen Del Río; Matilde Isabel Nuñez; Virginia Pubul; Michel Herranz Journal: Int J Mol Sci Date: 2015-02-18 Impact factor: 5.923
Authors: Stephen Hiscox; Bedanta Baruha; Chris Smith; Rebecca Bellerby; Lindy Goddard; Nicola Jordan; Zaruhi Poghosyan; Robert I Nicholson; Peter Barrett-Lee; Julia Gee Journal: BMC Cancer Date: 2012-10-06 Impact factor: 4.430
Authors: Franziska Heidemann; Anna Schildt; Katharina Schmid; Oliver T Bruns; Kristoffer Riecken; Caroline Jung; Harald Ittrich; Daniel Wicklein; Rudolph Reimer; Boris Fehse; Joerg Heeren; Georg Lüers; Udo Schumacher; Markus Heine Journal: PLoS One Date: 2014-04-03 Impact factor: 3.240